Quebec – Montreal – L'Île-Dorval
Corporation
www.supratek.com
Quebec
Montreal
L'Île-Dorval
Corporation
active
Supratek Pharma Inc. is a Montreal-based company with about 27
employees that was established in 1994. The company generates
new drug candidates by providing new therapeutic value to
existing drugs and newly discovered drugs and by creating novel
therapies in autoimmune, anti-viral and angiogenesis areas. The
company has eleven drug candidates in its pipeline to treat
various cancers, rheumatoid arthritis, viral diseases and
neurological disorders. This product pipeline has been created
using Supratek€™s proprietary Biotransportâ„¢ technology and an
information-based combinatorial approach called CombiFormâ„¢.
Supratek€™s first products to enter clinical trials are SP1049C
against refractory breast cancer and as a first line therapy for
oesophageal cancers and soft tissue sarcoma; SP1018R that blocks
the development of rheumatoid arthritis; and a novel water-
soluble formulation of paclitaxel, SP1010C with significantly
reduced toxicity.
Additionally, the Company has developed a powerful non-viral
gene delivery system. Independent testing by industry leaders
has demonstrated that this system is able to increase levels of
gene expression by 5-20 fold. Additionally, this system is able
to modify biological response by recruiting dendritic cells to
the site of administration. Both of these characteristics are
considered to be essential for the development of efficacious
DNA vaccines.
Technology Overview
Supratek's core technology, BiotransportTM, is based on highly
diverse chemistries that allow the creation of compounds for
pharmaceutical improvement. These compounds form self-assembled
colloid systems that solubilize drugs and act as delivery
vehicles within the body. In addition, BiotransportTM carriers
selectively sensibilize specific tissues and work as biological
response modifiers that allow the delivery of drug payloads to
specific tissues and inside cells.
The technology is designed to provide drugs with desirable
pharmacological properties, such as drug aqueous solubility,
cellular uptake, intracellular trafficking, biodistribution and
bioavailability, and improved metabolism rate.
CombiFormTM is Supratek's "toolbox" for drug formulation
optimization using BiotransportTM carrier technology. This
toolbox allows Supratek to manage BiotransportTM carrier
components in numerous combinations to design optimized carriers
to solve a drug compound's specific problem. CombiFormTM is
designed to quickly and economically increase the percentage of
drug leads that become clinical candidates and to increase their
probability of reaching the market.
Supratek is the outright owner of its patents. It's patent
estate covers the formulation, composition and use of block
copolymers in pharmaceutical applications. Supratek holds nine
U.S. patents. Three more have been allowed and 16 applications
are pending in the U.S. Corresponding international patents or
patent applications have been issued or are pending.
Country of Ownership: Canada
Year Established: 1994
Exporting: No
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Services
Total Sales ($CDN): $1 to $99,999
Number of Employees: 27
Services:
Biotechnology
Products:
Biotransportâ„¢ carrier technology, Anticancer, Cns, Anti-aids, Vegf antagonist, Gene therapy
Technology:
Supratek's core technology, BiotransportTM, is based on highly
diverse chemistries that allow the creation of compounds for
pharmaceutical improvement. These compounds form self-assembled
colloid systems that solubilize drugs and act as delivery
vehicles within the body. In addition, BiotransportTM carriers
selectively sensibilize specific tissues and work as biological
response modifiers that allow the delivery of drug payloads to
specific tissues and inside cells.
The technology is designed to provide drugs with desirable
pharmacological properties, such as drug aqueous solubility,
cellular uptake, intracellular trafficking, biodistribution and
bioavailability, and improved metabolism rate.
CombiFormTM is Supratek's "toolbox" for drug formulation
optimization using BiotransportTM carrier technology. This
toolbox allows Supratek to manage BiotransportTM carrier
components in numerous combinations to design optimized carriers
to solve a drug compound's specific problem. CombiFormTM is
designed to quickly and economically increase the percentage of
drug leads that become clinical candidates and to increase their
probability of reaching the market.
Supratek is the outright owner of its patents. It's patent
estate covers the formulation, composition and use of block
copolymers in pharmaceutical applications. Supratek holds nine
U.S. patents. Three more have been allowed and 16 applications
are pending in the U.S. Corresponding international patents or
patent applications have been issued or are pending.
Berg Karen
Romar Oleg
No associations
LandOfFree
Supratek Pharma Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with Supratek Pharma Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Supratek Pharma Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-14097